▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #938 by analyst upside · 2026-09-05
SLDB
Solid Biosciences Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+82.1%
implied upside to consensus target
Current Price $10.25
Consensus Target $18.67
Bull Target $26.0
Bear Target $11.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
8
Hold
0
Sell
0
52-Week Low $3.79
52-Week High $11.45
YTD Return +88.1%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.86
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.79
52-Week High $11.45
Current Price $10.25
Bear Target $11.0
Bull Target $26.0
● Now $10.25 ● Target $18.67
TRADING DATA
Avg Volume 1.6M
YTD Return +88.1%
Analyst Count 12
Consensus Buy
Upside to Target +82.1%
Last Updated 2026-09-05

ANALYST SUMMARY

Solid Biosciences Inc. (SLDB) is currently trading at $10.25 with a Wall Street consensus price target of $18.67, implying potential upside of 82.1% over the next 12 months. 12 analysts currently cover SLDB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $11.0.

SLDB operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 88.1% year-to-date and is currently trading near the upper end of its 52-week range of $3.79 – $11.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

APMD +83.4%
Apnimed, Inc.
$1B · P/E 11.4x · Buy
OMER +74.1%
Omeros Corporation
$1B · P/E 11.6x · Hold
INVA +64.1%
Innoviva, Inc.
$2B · P/E 4.9x · Buy
VOR +55.7%
Vor Biopharma Inc.
$1B · P/E 0.1x · Buy
NUTX +46.5%
Nutex Health Inc.
$1B · P/E 7.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SLDB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities - Reiterated
Buy → Buy 2026-08-21 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-03 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-05-18 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-05-13 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-13 14% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-03-25 43% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-23 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2026-03-20 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
20/30
Consensus clarity
1/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →